166 related articles for article (PubMed ID: 32259468)
1. Downgrading from Biopsy Grade Group 4 Prostate Cancer in Patients Undergoing Radical Prostatectomy for High or Very High Risk Prostate Cancer.
Ranasinghe W; Reichard CA; Nyame YA; Sundi D; Tosoian JJ; Wilkins L; Alam R; Achim MF; Wang X; Stephenson AJ; Klein EA; Ross AE; Allaf ME; Davis JW; Chapin BF
J Urol; 2020 Oct; 204(4):748-753. PubMed ID: 32259468
[TBL] [Abstract][Full Text] [Related]
2. Combined multiple clinical characteristics for prediction of discordance in grade and stage in prostate cancer patients undergoing systematic biopsy and radical prostatectomy.
Liu H; Tang K; Xia D; Peng E; Wang L; Chen Z
Pathol Res Pract; 2020 Nov; 216(11):153235. PubMed ID: 33035728
[TBL] [Abstract][Full Text] [Related]
3. Downgrading of biopsy based Gleason score in prostatectomy specimens.
Treurniet KM; Trudel D; Sykes J; Evans AJ; Finelli A; Van der Kwast TH
J Clin Pathol; 2014 Apr; 67(4):313-8. PubMed ID: 24403214
[TBL] [Abstract][Full Text] [Related]
4. Nomogram Predicting Downgrading in National Comprehensive Cancer Network High-risk Prostate Cancer Patients Treated with Radical Prostatectomy.
Wenzel M; Würnschimmel C; Chierigo F; Flammia RS; Tian Z; Shariat SF; Gallucci M; Terrone C; Saad F; Tilki D; Graefen M; Becker A; Kluth LA; Mandel P; Chun FKH; Karakiewicz PI
Eur Urol Focus; 2022 Sep; 8(5):1133-1140. PubMed ID: 34334344
[TBL] [Abstract][Full Text] [Related]
5. Factors associated with downgrading in patients with high grade prostate cancer.
Whitson JM; Porten SP; Cowan JE; Simko JP; Cooperberg MR; Carroll PR
Urol Oncol; 2013 May; 31(4):442-7. PubMed ID: 21478037
[TBL] [Abstract][Full Text] [Related]
6. Downgrading of grade group 2 intermediate-risk prostate cancer from biopsy to radical prostatectomy: Comparison of outcomes and predictors to identify potential candidates for active surveillance.
Su ZT; Patel HD; Epstein JI; Pavlovich CP; Allaf ME
Cancer; 2020 Apr; 126(8):1632-1639. PubMed ID: 32031685
[TBL] [Abstract][Full Text] [Related]
7. The Impact of Downgrading from Biopsy Gleason 7 to Prostatectomy Gleason 6 on Biochemical Recurrence and Prostate Cancer Specific Mortality.
Ham WS; Chalfin HJ; Feng Z; Trock BJ; Epstein JI; Cheung C; Humphreys E; Partin AW; Han M
J Urol; 2017 Apr; 197(4):1060-1067. PubMed ID: 27847296
[TBL] [Abstract][Full Text] [Related]
8. The role of PSMA PET/CT in predicting downgrading in patients with Gleason score 4+4 prostate cancer in prostate biopsy.
Aykanat IC; Kordan Y; Seymen H; Koseoglu E; Ozkan A; Esen B; Tarim K; Kulac I; Falay O; Gurses B; Baydar DE; Canda AE; Balbay MD; Demirkol MO; Esen T
World J Urol; 2024 May; 42(1):341. PubMed ID: 38771329
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer upgrading or downgrading of biopsy Gleason scores at radical prostatectomy: prediction of "regression to the mean" using routine clinical features with correlating biochemical relapse rates.
Altok M; Troncoso P; Achim MF; Matin SF; Gonzalez GN; Davis JW
Asian J Androl; 2019; 21(6):598-604. PubMed ID: 31115364
[TBL] [Abstract][Full Text] [Related]
10. Should all prostate needle biopsy Gleason score 4 + 4 = 8 prostate cancers be high risk? Implications for shared decision-making and patient counselling.
Ginsburg K; Cole AI; Silverman ME; Livingstone J; Smith DW; Heilbrun LK; Shi D; Mehra R; Sakr WA; Morgan TM; Cher ML
Urol Oncol; 2020 Mar; 38(3):78.e1-78.e6. PubMed ID: 31791703
[TBL] [Abstract][Full Text] [Related]
11. The impact of mpMRI-targeted vs systematic biopsy on the risk of prostate cancer downgrading at final pathology.
Sorce G; Stabile A; Pellegrino F; Mazzone E; Mattei A; Afferi L; Serni S; Minervini A; Roumiguiè M; Malavaud B; Valerio M; Rakauskas A; Marra G; Gontero P; Porpiglia F; Guo H; Zhuang J; Gandaglia G; Montorsi F; Briganti A
World J Urol; 2024 Apr; 42(1):248. PubMed ID: 38647689
[TBL] [Abstract][Full Text] [Related]
12. Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades.
Epstein JI; Feng Z; Trock BJ; Pierorazio PM
Eur Urol; 2012 May; 61(5):1019-24. PubMed ID: 22336380
[TBL] [Abstract][Full Text] [Related]
13. Clinical role of pathological downgrading after radical prostatectomy in patients with biopsy confirmed Gleason score 3 + 4 prostate cancer.
Gondo T; Poon BY; Matsumoto K; Bernstein M; Sjoberg DD; Eastham JA
BJU Int; 2015 Jan; 115(1):81-6. PubMed ID: 24725760
[TBL] [Abstract][Full Text] [Related]
14. Proportion of cores with the highest Gleason grade group among positive cores on prostate biopsy: does this affect the probability of upgrading or downgrading?
Yoo S; Suh J; Park J; Cho MC; Son H; Jeong H
Scand J Urol; 2019 Dec; 53(6):372-377. PubMed ID: 31674877
[No Abstract] [Full Text] [Related]
15. Over half of contemporary clinical Gleason 8 on prostate biopsy are downgraded at radical prostatectomy.
Qi R; Foo WC; Ferrandino MN; Davis LG; Sekar S; Longo TA; Jibara G; Han T; Gokhan I; Moul JW
Can J Urol; 2017 Oct; 24(5):8982-8989. PubMed ID: 28971784
[TBL] [Abstract][Full Text] [Related]
16. Most Gleason 8 Biopsies are Downgraded at Prostatectomy-Does 4 + 4 = 7?
Gansler T; Fedewa S; Qi R; Lin CC; Jemal A; Moul JW
J Urol; 2018 Mar; 199(3):706-712. PubMed ID: 29032296
[TBL] [Abstract][Full Text] [Related]
17. Prostate magnetic resonance imaging-targeted biopsy global grade correlates better than highest grade with prostatectomy grade.
Ren J; Melamed J; Taneja SS; Wysock JS; Huang WC; Lepor H; Deng FM
Prostate; 2023 Mar; 83(4):323-330. PubMed ID: 36461793
[TBL] [Abstract][Full Text] [Related]
18. Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading.
Donohue JF; Bianco FJ; Kuroiwa K; Vickers AJ; Wheeler TM; Scardino PT; Reuter VA; Eastham JA
J Urol; 2006 Sep; 176(3):991-5. PubMed ID: 16890678
[TBL] [Abstract][Full Text] [Related]
19. Postoperative upgrading of prostate cancer in men ≥75 years: a propensity score-matched analysis.
Herlemann A; Buchner A; Kretschmer A; Apfelbeck M; Stief CG; Gratzke C; Tritschler S
World J Urol; 2017 Oct; 35(10):1517-1524. PubMed ID: 28493044
[TBL] [Abstract][Full Text] [Related]
20. Upgrading and downgrading of prostate needle biopsy specimens: risk factors and clinical implications.
Freedland SJ; Kane CJ; Amling CL; Aronson WJ; Terris MK; Presti JC;
Urology; 2007 Mar; 69(3):495-9. PubMed ID: 17382152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
